news
Alcon gains exclusive ex-US rights for ocriplasmin
16 March 2012 | By Novartis
Potential first pharmacological treatment for symptomatic vitreomacular adhesion...
List view / Grid view
Novartis
news
Signifor® is first therapy to provide rapid, durable benefit for Cushing’s disease patients
7 March 2012 | By Novartis
A study found that the investigational drug Signifor®, normalized cortisol levels...
news
Brian McNamara named Division Head, Novartis OTC
29 February 2012 | By Novartis
Novartis named Brian McNamara to the position of Division Head of Novartis OTC (Over-the-Counter), effective immediately...
news
Two Phase III studies of Novartis drug INC424 published in NEJM show significant clinical benefit for patients with myelofibrosis
29 February 2012 | By Novartis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis...
news
European Commission approves new label for Novartis drug Glivec®
27 February 2012 | By Novartis
The European Commission has approved an update to the Glivec® (imatinib)* label...
news
Novartis to revise product information in the European Union for high blood pressure drug Rasilez®
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
news
FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®
13 February 2012 | By Novartis
Novartis has received a Complete Response letter from the US FDA...
news
Novartis drug Galvus® approved in EU for monotherapy use in patients with type 2 diabetes unable to take metformin
6 February 2012 | By Chamberlain Healthcare PR
The European Commission has approved the use of Galvus® (vildagliptin)...
news
FDA approves Novartis drug Glivec® label
1 February 2012 | By Novartis
The US Food and Drug Administration has approved an update to the Glivec® (imatinib)* label...
news
Novartis extends commitment to help achieve final elimination of leprosy
30 January 2012 | By Novartis
Novartis is a part of an international effort to eliminate or control 10 NTDs by the end of the decade...
news
CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery
20 January 2012 | By Novartis
Update of the Glivec® (imatinib)* label...
news
Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment
19 January 2012 | By Novartis
Sandoz announced that it has initiated two milestone Phase III clinical trials...
news
Novartis receives approval for Lucentis® and launches Galvus® in China
18 January 2012 | By Novartis
Novartis has received regulatory approval in China from the SFDA for Lucentis® (ranibizumab)...
news
Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent
13 January 2012 | By Novartis
US General Medicines restructuring results in reduction of 1,960 positions...
news
Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products in the US
8 January 2012 | By Novartis
There have been no related adverse events reported with the issues leading to the recall...
